Enanta Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $18,314 | $14,926 | $16,959 | $14,607 |
Gross Profit | 18,314 | 14,926 | 16,959 | 14,607 |
EBITDA | -15,398 | -21,032 | -19,855 | -26,126 |
EBIT | -16,608 | -22,235 | -20,744 | -26,605 |
Net Income | -18,255 | -22,644 | -22,290 | -28,823 |
Net Change In Cash | 18,314 | 14,926 | 16,959 | 14,607 |
Free Cash Flow | 17,351 | -16,026 | -25,546 | -19,351 |
Cash | 44,812 | 60,213 | 84,349 | 37,233 |
Basic Shares | 21,322 | 21,355 | 21,238 | 21,190 |
Annual Financials
| Values in thousands | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|
Revenue | $67,635 | $79,204 | $86,160 | $97,074 |
Gross Profit | 67,635 | 79,204 | 86,160 | 97,074 |
EBITDA | -104,512 | -123,476 | -119,215 | -106,239 |
EBIT | -106,848 | -125,847 | -122,188 | -109,573 |
Net Income | -116,045 | -133,816 | -121,755 | -78,996 |
Net Change In Cash | 67,635 | 79,204 | 86,160 | 97,074 |
Cost of Revenue | -9,852 | -29,925 | ||
Free Cash Flow | -96,712 | -112,212 | -86,907 | -70,746 |
Cash | 37,233 | 85,388 | 43,994 | 57,206 |
Basic Shares | 21,157 | 20,969 | 20,603 | 20,171 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.85 |
2025-03-31 | -$1.06 |
2024-12-31 | -$1.05 |
